Eagle Pharmaceuticals

RYANODEX

dantrolene sodium

Peak

INTRAVENOUS · FOR SUSPENSION

CLINICAL PHARMACOLOGY In isolated nerve-muscle preparation, dantrolene sodium has been shown to produce relaxation by affecting the contractile response of the skeletal muscle at a site beyond the myoneural junction, directly on the muscle itself. In skeletal muscle, dantrolene sodium dissociates the excitation contraction coupling, probably by interfering with the release of Ca from the sarcoplasmic reticulum. This effect appears to be more pronounced in fast muscle fibers as compared to slow ones, but generally affects both. A central nervous system effect occurs, with drowsiness, dizziness, and generalized weakness occasionally present. Although dantrolene sodium does not appear to directly affect the CNS, the extent of its indirect effect is unknown. The absorption of dantrolene sodium after oral administration in humans is incomplete and slow but consistent, and dose-related blood levels are obtained. The duration and intensity of skeletal muscle relaxation is related to the dosage and blood levels. The mean biologic half-life of dantrolene sodium in adults is 8.7 hours after a 100-mg dose. Specific metabolic pathways in the degradation and elimination of dantrolene sodium in human subjects have been established. Metabolic patterns are similar in adults and pediatric patients. In addition to the parent compound, dantrolene, which is found in measurable amounts in blood and urine, the major metabolites noted in body fluids are the 5-hydroxy analog and the acetamido analog. Since dantrolene sodium is probably metabolized by hepatic microsomal enzymes, enhancement of its metabolism by other drugs is possible. However, neither phenobarbital nor diazepam appears to affect dantrolene sodium metabolism. Clinical experience in the management of fulminant human malignant hyperthermia, as well as experiments conducted in malignant hyperthermia susceptible swine, have revealed that the administration of intravenous dantrolene, combined with indicated supportive measures, is effective in reversing the hypermetabolic process of malignant hyperthermia. Known differences between human and swine malignant hyperthermia are minor. The prophylactic administration of oral or intravenous dantrolene to malignant hyperthermia susceptible swine will attenuate or prevent the development of signs of malignant hyperthermia in a manner dependent upon the dosage of dantrolene administered and the intensity of the malignant hyperthermia triggering stimulus. Limited clinical experience with the administration of oral dantrolene to patients judged malignant hyperthermia susceptible, when combined with clinical experience in the use of intravenous dantrolene for the treatment of malignant hyperthermia and data derived from the above cited animal model experiments, suggests that oral dantrolene will also attenuate or prevent the development of signs of human malignant hyperthermia, provided that currently accepted practices in the management of such patients are adhered to (

Pipeline & Clinical Trials

i-STAT Alinity TBI test

TBI (Traumatic Brain Injury)

N/A

Clinical Trials (1)

NCT07373509Emergency Department Implementation of the i-STAT Alinity Traumatic Brain Injury Whole Blood Test

N/A

Liquefied petroleum gas

Infant, Low Birth Weight

N/A

Amphotericin B Liposome for Injection

Invasive Fungal Infections

N/A

Clinical Trials (1)

NCT06977490Human Bioequivalence Study of Amphotericin B Liposome for Injection

N/A

Fulvestrant for Injectable Suspension

Pharmacokinetics

PHASE_1

Clinical Trials (1)

NCT03324061Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration

Phase 1

Test Product

Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate

PHASE_1

Clinical Trials (1)

NCT02162888A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients

Phase 1

SeeMore

Myocardial Infarction

PHASE_2

Clinical Trials (1)

NCT00881075Safety and Efficacy of SeeMore (TM) in Heart Patients

Phase 2

CAL02

Pneumonia, Bacterial

PHASE_2

Clinical Trials (1)

NCT05776004Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia

Phase 2

OPAL A

Venous Ulcer

PHASE_2

Clinical Trials (1)

NCT00933348Safety and Efficacy of the Fruit-based Product OPAL A for the Treatment of Chronic Venous and Pressure Ulcers

Phase 2

Dantrolene sodium for injectable suspension

Heat Stroke

PHASE_2

Clinical Trials (1)

NCT02513095Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)

Phase 2

Ryanodex

Drug Toxicity Psychotropic Agents Psychostimulants

PHASE_2

Clinical Trials (1)

NCT03189433Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)

Phase 2

Ryanodex and Standard of Care

Exertional Heat Stroke

PHASE_3

Clinical Trials (1)

NCT03600376Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS

Phase 3

Placebo

Mild to Moderate Ulcerative Colitis

PHASE_3

Clinical Trials (1)

NCT01045018A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis

Phase 3

Arm 1 Cataract Surgery performed with remimazolam as sedative

Cataract Surgery Anesthesia

PHASE_4

Clinical Trials (1)

NCT07325227Study of Remimazolam for Cataract Surgery

Phase 4

About Eagle Pharmaceuticals

Why Work Here

Key Products

Watch Out For

Products & Portfolio (4)

Key Products by Revenue

Other Products (3)

Pipeline & Clinical Trials

Recent News · Eagle Pharmaceuticals(6)

Open Jobs (0)

Hiring Trend

Research Publications(7)